School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.
Center of Clinical Epidemiology and Evidence Based Medicine, Shanxi Medical University, Taiyuan, Shanxi, China.
Hum Vaccin Immunother. 2022 Dec 31;18(1):2029259. doi: 10.1080/21645515.2022.2029259. Epub 2022 Mar 16.
Whether telbivudine (LdT) treatment to pregnant women with hepatitis B surface antigen (HBsAg) affects infant immune response to hepatitis B vaccine (HepB) has not been investigated. A total of 127 HBsAg positive mothers and their neonates were enrolled and followed up at 11-13 months. Mothers took LdT (LdT group) or did not receive antiviral therapy (control group). Infant anti-HBs, immune cells and cytokines were measured after HepB was administered according to 0-1-6 procedure. We performed a 1:3 propensity score matching (PSM). Immune indexes in the two groups were compared. Baseline characteristics of mother-baby pairs were comparable in LdT group and control group. Infant anti-HBs geometric mean concentration (GMC) did not differ significantly between the two groups [767.70 (745.35) vs. 711.90 (819.60), = .599]. There was no difference between the two groups in infant positive rate of anti-HBs [97.8% (91/93) vs. 97.1% (33/34), = .999] and strong positive rate of anti-HBs [40.9% (38/93) vs. 44.1% (15/34), = .742]. Infants with negative, low, medium, and high anti-HBs levels were similarly distributed between the two groups ( = .511). No differences in proportion of helper T cells, cytotoxic T cells, B cells, myeloid dendritic cells, and plasmacytoid dendritic cells of infants ( > .05) were detected between the two groups. Children in the LdT and control group had comparable levels of interleukin-2, interleukin-4, interleukin-6, interleukin-10, interleukin-12, interferon-α, interferon-γ and tumor necrosis factor-α ( > .05). Intrauterine exposure to LdT was safe to infant immune response to HepB after birth.
替比夫定（LdT）治疗乙型肝炎表面抗原（HBsAg）阳性的孕妇是否会影响婴儿对乙型肝炎疫苗（HepB）的免疫应答尚未得到研究。共纳入 127 例 HBsAg 阳性母亲及其新生儿，在 11-13 个月时进行随访。母亲接受 LdT（LdT 组）或未接受抗病毒治疗（对照组）。根据 0-1-6 程序接种 HepB 后，检测婴儿抗-HBs、免疫细胞和细胞因子。我们进行了 1:3 的倾向评分匹配（PSM）。比较两组的免疫指标。LdT 组和对照组的母婴配对的基线特征无显著差异。两组婴儿抗-HBs 几何平均浓度（GMC）无显著差异[767.70（745.35）比 711.90（819.60）， = .599]。两组婴儿抗-HBs 阳性率[97.8%（91/93）比 97.1%（33/34）， = .999]和强阳性率[40.9%（38/93）比 44.1%（15/34）， = .742]无差异。两组婴儿抗-HBs 阴性、低、中、高水平的分布相似（ = .511）。两组婴儿辅助 T 细胞、细胞毒性 T 细胞、B 细胞、髓样树突状细胞和浆细胞样树突状细胞的比例无差异（ > .05）。两组婴儿白细胞介素-2、白细胞介素-4、白细胞介素-6、白细胞介素-10、白细胞介素-12、干扰素-α、干扰素-γ和肿瘤坏死因子-α的水平无差异（ > .05）。
替比夫定宫内暴露对婴儿出生后对 HepB 的免疫应答是安全的。
